Fluvoxamine (DU-23000) is a selective, orally available 5-HT and serotonin reuptake inhibitor (SSRI) exhibiting antidepressant effects.

Fluvoxamine effectively inhibits the uptake of serotonin (5-HT) by platelets and brain synaptosomes [1].
The antagonistic effect of fluvoxamine on reserpine-induced lowering of pentylenetetrazol (PTZ) seizure threshold can be attributed to its influence on 5-HT uptake [1].
In contrast to desipramine and imipramine, fluvoxamine did not elicit stimulant effects in rats after administration of a rapidly acting reserpine-like compound [1].
Fluvoxamine improves combat-related PTSD symptoms but is ineffective for depressive symptoms [2]. Due to high dropout rates and the lack of a placebo control group, the reliability of current findings is limited, and future controlled studies on fluvoxamine for PTSD treatment are needed [2].
When ethanol is available with food, fluvoxamine is less effective in reducing ethanol self-administration than when ethanol is available alone [ED₅₀ values were 4.0 (2.7–5.9) and 5.1 (4.3–6.0), respectively] [3]. Under each condition where food was available, fluvoxamine had no significant effect on food intake [3]. These results indicate that the efficacy of fluvoxamine in suppressing ethanol-maintained behavior is influenced by whether ethanol is concurrently available with food reinforcement [3].

DMSO: 125 mg/mL (392.67 mM), Sonication is recommended.

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (10.37 mM), Sonication is recommended.